Smaller Prostate Size Predicts High Grade Prostate Cancer at Final Pathology
Mark R. Newton(University of Iowa), Daniel A. Barocas(Vanderbilt University Medical Center), Michael S. Cookson(University of Oklahoma Health Sciences Center), S. Duke Herrell(Vanderbilt University Medical Center), Jay H. Fowke(Vanderbilt University Medical Center), Peter E. Clark(Levine Cancer Institute), Rodney Davis(The University of Texas MD Anderson Cancer Center), Joseph A. Smith(King's College London), Robert Chan(Vanderbilt University Medical Center), Sam S. Chang(Vanderbilt University), Vineet Mishra(Emory University), Roxelyn G. Baumgartner(Vanderbilt University Medical Center), Sharon Phillips(Vanderbilt University Medical Center), Jeffrey D. Blume(Vanderbilt University)
Cited by 63
Related Papers
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
|New England Journal of Medicine|2003|2k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592